1-Adamantanamine

1-Adamantanamine CAS 768-94-5 was the earliest antiviral drug used to inhibit influenza viruses. In 1966, the United States approved it as a preventive medicine during the Asian flu pandemic, and in 1976, it was confirmed as a therapeutic drug on the basis of preventive medicine. The efficacy and safety of this drug for adult patients have been widely recognized. However, the therapeutic dose is very close to the dose that produces side effects, making it difficult to determine the dosage and administration plan for elderly individuals and those with chronic heart, lung, or kidney disease. Therefore, it has not been widely promoted and applied in clinical practice. In Japan, 1-Adamantanamine CAS 768-94-5 has been used as a therapeutic drug for Parkinson's disease until 1998, when it was approved for the treatment of influenza virus type A infectious diseases.

1-Adamantanamine CAS 768-94-5 is an antiviral drug with anti influenza A virus activity. 1-Adamantanamine CAS 768-94-5 prevents protons from passing through the M2 ion channel (the M2 proton channel of influenza A), thereby preventing the release of viral RNA into the cytoplasm of infected cells. 1-Adamantanamine CAS 768-94-5 has an antipyretic effect, and when used in combination with multiple anti-inflammatory and antibacterial drugs, the therapeutic effect is better than using antibiotics alone.

1-Adamantanamine CAS 768-94-5 is an anti Parkinson's disease drug. The mechanism of action in treating Parkinson's disease is not yet clear, which may be related to the promotion of dopamine (DA) release from dopaminergic nerve endings in the striatum by 1-Adamantanamine CAS 768-94-5, and the enhancement of dopamine and catecholamine effects in the central nervous system, increasing the dopamine content of neurons. Animal experiments have also shown that the use of 1-Adamantanamine CAS 768-94-5 increases dopamine release in the animal brain. 1-Adamantanamine CAS 768-94-5 is still an antiviral drug against RNA viruses, and its mechanism of action is not fully understood. Can prevent RNA viruses from penetrating host cells. If the virus has penetrated the host cell, it can also prevent the virus from uncoating and releasing nucleic acids, interfering with the early replication of the virus.

In addition, it can also block the virus channels on the host cell membrane, preventing the virus from penetrating human cells. In tissue culture, 1-Adamantanamine CAS 768-94-5 can prevent the infection of mucovirus and paramucovirus, and is also effective against in vitro rhabdovirus. However, in clinical practice, it only has an effect on type A influenza virus. Although all the latest natural influenza A viruses are sensitive to 1-Adamantanamine CAS 768-94-5, drug-resistant mutations can be observed in virus strains exposed to 1-Adamantanamine CAS 768-94-5 in tissue culture. The mechanism of drug resistance is RNA mutation. In clinical practice, 1-Adamantanamine CAS 768-94-5 does not have anti influenza B virus and parainfluenza virus effects. It has a relieving effect on various types of Parkinson's disease, and the therapeutic effect is stronger than that of anticholinergic drugs but weaker than levodopa. After taking it, it shows significant effect for 2 weeks and lasts for 4-8 weeks. 1-Adamantanamine CAS 768-94-5 has inhibitory activity against the Asian influenza A virus, inhibiting virus proliferation. Timely medication is also effective for patients who have already developed the disease, which can cause a decrease in body temperature within 24 hours and significantly alleviate symptoms within approximately 36 hours.